CytoCares Inc.
Clinical trials sponsored by CytoCares Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New 'Smart' immune therapy takes on lupus and arthritis Results expected Nov 2026 (estimated)
- New lupus drug CC312 enters first human safety trial Results expected Sep 2027 (estimated)
-
Tiny early trial launches for new autoimmune drug
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multip…
Early phase 1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for tough blood cancers? early trial launches
Disease control Recruiting nowThis early-stage study is testing a new biologic drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check safety and find the right dose. Participants receive CC31…
Phase 1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New 'Smart' immune therapy takes on lupus and arthritis
Disease control Recruiting nowThis early-phase study is testing a new drug called CC312 in 18 adults with severe autoimmune diseases like lupus and rheumatoid arthritis that haven't improved with standard treatments. CC312 is a type of immune therapy designed to target and destroy faulty B cells, similar to C…
Early phase 1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 26, 2026 18:43 UTC
-
New lupus drug CC312 enters first human safety trial
Disease control Recruiting nowThis early-stage study tests a new drug, CC312, in 32 adults with moderate-to-severe systemic lupus erythematosus (SLE). Participants receive either CC312 or a placebo intravenously to check for safety, side effects, and how the drug moves through the body. The goal is to see if …
Phase 1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 26, 2026 17:46 UTC